哒嗪酮类新衍生物的合成及其对血小板聚集的抑制作用

6-(4-取代苯基)哒嗪酮类衍生物具有较强的抑制血小板聚集作用.设计并合成了6-(4-取代苯基)-5-甲基-4,5-二氢-3(2H)哒嗪酮类化合物.以乙酰苯胺为原料,经付-克酰化反应、氰化、水解、水合肼环化反应合成目标化合物,并参考Born方法进行体外药理实验.目标化合物通过1H NMR,MS,IR,元素分析等证实了其结构.体外药理实验表明,目标化合物对二磷酸腺苷(ADP)诱导的人血小板聚集均有较强的抑制作用.     

2,3-二氢喹唑啉-4(1H)-酮类化合物的合成研究进展

2,3-二氢喹唑啉-4(1H)-酮是一类重要的含氮稠杂环化合物,具有广泛的药理及生物活性,在药物合成与研发领域有着重要应用价值,因而其合成方法也倍受人们关注.归纳总结了2,3-二氢喹唑啉-4(1H)-酮类化合物的合成研究进展,主要介绍了以邻氨基苯甲酰胺、靛红酸酐、邻硝基苯甲酰胺、邻叠氮基苯甲酰胺、邻溴苯甲酰胺、邻溴苯甲腈、邻氨基苯甲酸、邻氨基苯甲腈、邻氨基N-甲基-N-丙二烯基苯甲酰胺、N-烷基苯胺等为起始原料的2,3-二氢喹唑啉-4(1H)-酮类化合物的合成研究进展概况及其反应机理.最后对该类化合物的合成研究进展进行了总结,并对其发展前景进行了展望.     

1-甲基-3-芳基-6-三氟甲基哒嗪-4-酮类化合物的合成与生物活性

在现有原卟啉原氧化酶抑制剂构效关系基础上,设计了一类结构新颖的3-芳基哒嗪酮类化合物,并探索了该类化合物的合成方法,合成了9个3-芳基哒嗪酮类化合物,并用于开展室内除草活性测定和作物安全性评价.结果表明3-芳基哒嗪酮类化合物具有较高的芽前、芽后除草活性和作物安全性.对高活性化合物3-[2,4-二氯-5-(环戊氧基)苯基]-1-甲基-6-(三氟甲基)哒嗪-4(1H)-酮(Ie)进行了苗后玉米田间小区药效验证试验,结果表明化合物Ie在60 g a.i./hm2剂量下的总草防效略高于105 g a.i./ha用量的硝磺草酮,且对苗后玉米安全.     

2-异丙基-1,3-二氢-4(1H)异喹啉酮及其衍生物的合成

异喹啉酮类化合物具有重要药理活性,本文在合成1,2,3,4-四氢-2-苄基异喹啉酮-4衍生物的基础上,参照Hinton方法制备2-异丙基-1,3-二氢-4(1H)异喹啉酮(1),用(1)进一步与芳醛、羟胺、酰氯及苯肼反应得到了相应的衍生物(3_a-6_e)。     

1-芳基-1，4二氢-3芳酰肼基甲酰基-6甲基-4-哒嗪酮的合成及对黄瓜子叶生根作用的构效关系研究

合成了一系列的1-芳基-1，4-二氢-3-芳酰肼基甲酰基-各甲基斗哒嗪酮类化合 物，并用离体黄瓜子叶生根法测试其生物活性，生测结果表明，所有的化合物均显 示出一定的生物活性，并且芳环上的取代基对活性有重要影响．采用化合物的物理 化学参数及化合物促进黄瓜子叶生根的活性，进行了结构与活性定量关系研究，建 立了较好的结构与活性的相关式，化合物的亲脂性和取代基的电性对化合物的生物 活性具有重要的影响．研究结果对3-芳酰肼基甲酰基斗哒嗪酮类化合物的改性或新 类似物的合成具有指导意义．     

4-氟-1,2-二氢-3,6-哒嗪二酮及其衍生物的合成

本文报导了4-氟-1,2-二氢-3,6-哒嗪二酮(Ⅱ)及其衍生物3,6-二氯-4-氟哒嗪(Ⅲ)、3-甲氧基-4-氟-6-氯哒嗪(Ⅳ)、3-邻甲苯氧基-4-氟-6-氯哒嗪(Ⅵ)、1-苯基-3-羟基-4-氟-6-哒嗪酮(Ⅶ)等五种新化合物的合成,探讨了(Ⅲ)同亲核试剂的反应性能和部分化合物的药理实验结果.     

3a, 4-二氢-苯并吡喃[4,3-c]吡唑-3(2H)-酮类衍生物的合成及其活性

设计合成了33种新型的3a, 4-二氢-苯并吡喃[4,3-c]吡唑-3(2H)-酮类化合物,其结构经MS,1H NMR和元素分析的确证。并对化合物7k的单晶进行了结构测定。初步生物活性测试表明标题化合物具有一定的杀虫杀菌活性。     

1-取代-1,4,5,6-四氢(及1,6-二氢)-6-哒嗪酮-3-酰肼衍生物的合成

哒嗪类化合物具有抗原虫,抗鞭毛虫及阿巴米等多种药理活性,一些6-芳基-4,5-3(2H)哒嗪酮具有抗高血压,利尿及中枢神经抑制作用[1],并且哒嗪类化合物在农药方面也有广泛的应用[2].另外酰氨基硫脲及其衍生物具有广谱的抗菌和杀虫作用.本文以α-酮戊二酸和水合肼为起始原料,合成哒嗪酰肼[3],将其酰肼与糖基异硫氰酸酯或芳香烃异硫氰酸酯反应,合成哒嗪酮酰氨基硫脲及衍生物.其药理活性有待测试.     

新型化学杂交剂哒嗪酮衍生物的合成及其对小麦去雄活性研究

从吡喃酮与不同的芳基重氮盐的偶联反应制备了1,4-二氢-3-羧基哒嗪-4-酮类化合物,并首次以它们为原料分别与氨基硫脲和肼或苯肼进行环合反应得到了两类去雄化学杂交剂杂环化合物--哒嗪酮氨基噻唑以及哒嗪吡唑酮化合物.初步去雄活性实验显示哒嗪酮氨基噻唑盐酸盐类化合物在较高剂量时具有去雄活性,在剂量为2100g/ha时去雄率达99%左右.     

2-芳基-3-乙酰基-5-[1,4,5,6-四氢-(1,6-二氢)-6-哒嗪酮-3-基]噁二唑啉的合成

双杂环类化合物的合成及生物活性研究已经成为有机化学中最具生命力的研究课题之一.研究表明某些哒嗪酮类化合物具有较强的降压、强心、抗病毒等生物活性[1],有些还具有抗抑郁作用[2].以哒嗪酮为先导化合物,对哒嗪酮的不同位置进行修饰,可得到药效不同的化合物[3].本文以α-酮戊二酸和水合肼为起始原料,设计了如下所示的合成路线,得到了20个未见文献报道的哒嗪酮类衍生物.     

Synthesis and platelet aggregation inhibitory activities of 3-(2-oxopropylidene)azetidin-2-one derivatives. II.

A series of 3-acylidene-4-methylazetidin-2-one derivatives bearing various substituents at the 1-position of the azetidin-2-one ring was synthesized. These compounds were evaluated for platelet aggregation inhibitory activities. Most of the compounds synthesized showed potent inhibitory activities against rabbit platelet aggregation induced by adenosine diphosphate or collagen in vitro. Structure-activity relationships are also discussed.     

4(6)-{2-[4-(2,3,4-三甲氧基苄基)哌嗪-1-基]-2-氧代乙氧基}芳甲酰胍类化合物的合成及其Na~+/H~+交换器1抑制活性

NHE1(Na+/H+交换器1)抑制剂对于心肌缺血再灌注损伤具有较好的保护作用.以苯(或吡啶)甲酰胍为母核,利用拼合原理,在苯(或吡啶)甲酰胍母环上引入4-(2,3,4-三甲氧基苄基)哌嗪-1-甲基,设计并合成了8个未见文献报道的目标化合物.其结构经MS,IR,1H NMR和元素分析确证.体外血小板肿胀模型(PSA)试验结果表明,大部分目标化合物显示出较好的NHE1抑制活性.     

Synthesis and pharmacological evaluation of some 3-(4-methoxyphenyl)-2-substitutedamino-quinazolin-4(3H)-ones as analgesic and anti-inflammatory agents

A variety of novel 3-(4-methoxyphenyl)-2-substitutedamino-quinazolin-4(3H)-ones were synthesized by reacting the amino group of 2-hydrazino-3-(4-methoxyphenyl)-quinazolin-4(3H)-one with a variety of alkyl and aryl ketones. The starting material 2-hydrazino-3-(4-methoxyphenyl)-quinazolin-4(3H)-one was synthesized from 4-methoxyaniline. The title compounds were investigated for analgesic, anti-inflammatory and ulcerogenic index activities. While the test compounds exhibited significant activity, compounds 2-(1-methylpropylidene)-hydrazino-3-(4-methoxyphenyl)-quinazolin-4(3H)-one (A1), 2-(1-ethylpropylidene)-hydrazino-3-(4-methoxyphenyl)-quinazolin-4(3H)-one (A2) and 2-(1-methylbutylidene)-hydrazino-3-(4-methoxyphenyl)-quinazolin-4(3H)-one (A3) showed moderately more potent analgesic activity and the compound 2-(1-methylbutylidene)-hydrazino-3-(4-methoxyphenyl)-quinazolin-4(3H)-one (A3) showed moderately more potent anti-inflammatory activity when compared to the reference standard diclofenac sodium. Interestingly the test compounds showed only mild ulcerogenic potential when compared to aspirin.     

Thromboxane A2 receptor antagonists. III. Synthesis and pharmacological activity of 6,6-dimethylbicyclo[3.1.1]heptane derivatives with a substituted sulfonylamino group at C-2

Four stereoisomers of the title compounds based on side chain ring junctions, (+)-7a, (+)-7b, (-)-7c and (-)-24, were synthesized from (-)-myrtenol and (+)-nopinone. The (1R,2R,3S,5S)-isomer (+)-7b had the most potent inhibitory activity against platelet aggregation and did not show partial agonist activity (shape change of platelets). We also synthesized the antipode, (-)-7b, and derivatives of (+)-7b with various kinds of substituents at the sulfonylamino group, 34a-n and p. The one-carbon homologated compound, (+)-58, was also prepared. The inhibitory activities of these compounds against platelet aggregation were measured.     

((吡啶-3-基)甲氧基)芳酸衍生物的合成及抗血小板聚集活性

以具有活血化瘀作用的中药有效成分阿魏酸为先导物,按生物电子等排原理,设计合成了6个((吡啶-3-基)甲氧基)芳酸衍生物,其结构经IR,1H NMR,13C NMR及MS确证.体外药效筛选结果显示,部分((吡啶-3-基)甲氧基)芳酸衍生物对二磷酸腺苷(ADP)诱导的血小板聚集具有较好的抑制活性,其中化合物1a的抑制作用明...     

Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acids

To improve the in vitro and in vivo potency of our first low molecular weight GPIIb/IIIa antagonist 1 (TAK-029), a series of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiper-azinyllacetic acids were synthesized through modification of the glycine moiety of 1 and evaluated for their ability to inhibit in vitro adenosine 5'-diphosphate (ADP)-induced platelet aggregation of guinea pig platelet rich plasma (PRP). Among the compounds examined, the (3S,2S)-4-methoxyphenylalanine derivative 4h showed the most potent antagonistic activity with an IC50 value of 13 nM. Dose-dependent inhibition of ex vivo platelet aggregation was achieved with oral administration of 4h (0.3-1.0 mg/kg) to guinea pigs. Complete inhibition was observed for up to 8 h, and 43% inhibition could still be observed 24 h after oral administration of 1.0 mg/kg. The long-lasting antiplatelet effect of 4h suggests that 4h would be suitable for once-a-day dosing. Structure-activity relationships (SAR) were examined in the series of the phenylalanine derivatives. An increase in the electron density around the 4-position of the phenyl ring of the phenylalanine moiety led to an increase in the antiplatelet activity, suggesting the existence of a hydrophobic and electrostatic interaction site in addition to the ionic binding sites in the GPIIb/IIIa.     

Studies on new platelet aggregation inhibitors 1. Synthesis of 7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives.

A series of 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-ones were prepared and tested for platelet aggregation inhibitory effect, cardiotonic activity and chronotropic activity. These compounds appeared to show selective inhibitory activity against platelet aggregation. Among them, 6-(4-ethoxycarbonylpiperidino)-7-nitro-3,4-dihydroquinoline-2(1H)-one (22f) showed the most potent inhibitory activity and high selectivity. A divergent synthetic route to 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives has also been investigated.     

Synthesis and platelet aggregation-inhibitory activities of novel 3-(2-oxopropylidene)azetidin-2-one derivatives. I

Treatment of (E)-3-(2-hydroxypropylidene)-4-methyl-1-phenylazetidin-2-one (11) with 10% Pd/C gave (E)-(12), (Z)-3-(2-oxopropylidene)-4-methyl-1-phenylazetidin-2-one (13), 3,4-cis-(14a) and 3,4-trans-3-(2-oxopropyl)-4-methyl-1-phenylazetidin-2-one (14b). Among them, 12 and 13 were found to show potent inhibitory activities against rabbit platelet-rich plasma aggregation induced by adenosine diphosphate or collagen. Ring-expanded homologous derivatives and an acyclic analogue of 12 were also synthesized and tested for the biological activities. The azetidin-2-one skeleton bearing a 2-oxoalkylidene moiety at the 3 position was found to be essential for the platelet aggregation inhibitory activities of these compounds.     

新型N-(4,6-二取代嘧啶-2-基)-1-[取代吡啶(噻唑)甲基]-5-甲基-1H-1,2,3-三唑基-4-甲酰胺的合成与除草活性

为了寻找新型低毒性的潜在除草剂, 以2-氯-5-(氯甲基)吡啶和2-氯-5-(氯甲基)噻唑为起始原料, 经过叠氮化, 然后与乙酰乙酸乙酯的环化, 水解, 卤化, 最后与2-氨基-4,6-二取代嘧啶的缩合反应, 合成了9种未见文献报道的目标化合物, 其结构经IR, ¹H NMR, MS 和元素分析确证. 初步的生物活性测试结果表明, 所测目标化合物在100 mg/L浓度下显示出良好的除草活性.